专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140011823A1 NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME 有权
标题翻译：新颖的吡啶衍生物和含有其的药物
公开(公告)号：US20140011823A1
公开(公告)日：2014-01-09
申请号：US14005046
申请日：2012-03-13
申请人： Toru Miura , Seiichi Sato , Hajime Yamada , Junya Tagashira , Toshiaki Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
发明人： Toru Miura , Seiichi Sato , Hajime Yamada , Junya Tagashira , Toshiaki Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
IPC分类号： C07D413/14 , C07D401/14
CPC分类号： C07D413/14 , A61K31/506 , C07D401/14
摘要： The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPARγ activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents an alkyl group; R2 represents an alkyl group or a cycloalkyl group; and R3, R4, and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar.
摘要翻译：本发明提供：下述通式（I）表示的化合物，既具有血管紧张素II受体拮抗作用又具有PPARγ活化作用，可用作高血压，心脏病，动脉硬化等的预防和/或治疗剂， 2型糖尿病等; 和含有该化合物的药物组合物。通式（I）（式中，环A表示吡啶环;环B表示四唑环或恶二唑-5（4H） - 酮环; X表示C-R5或氮原子; R1表示烷基 ; R 2表示烷基或环烷基; R 3，R 4和R 5各自独立地表示氢原子，卤素原子，烷基，烷氧基等。

2. 发明申请

US20120322819A1 COMPOUND CONTAINING A NOVEL 4-ALKOXYPYRIMIDINE STRUCTURE AND MEDICINE CONTAINING SAME 审中-公开
标题翻译：含有新型4-烷氧基嘧啶结构的化合物和含有其的药物
公开(公告)号：US20120322819A1
公开(公告)日：2012-12-20
申请号：US13580056
申请日：2011-02-25
申请人： Toru Miura , Kazuhiro Onogi , Junya Tagashira , Gen Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
发明人： Toru Miura , Kazuhiro Onogi , Junya Tagashira , Gen Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
IPC分类号： A61K31/506 , C07D413/14 , A61P9/00 , A61P3/04 , A61P9/10 , A61P3/00 , A61P3/10 , C07D413/10 , A61P9/12
CPC分类号： C07D413/10 , C07D413/14
摘要： Disclosed is novel compound and medicinal formulation containing same, possessing both angiotensin II receptor blocking and PPARγ activation effect, of use as a medicine for prevention and/or treatment of hypertension, heart disease, angina pectoris, cerebrovascular disorder, cerebral circulatory disturbances, post-ischemic peripheral circulatory damage, renal disease, arteriosclerosis, inflammatory disorder, type 2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinaemia. Further disclosed is the general formula I (where one or both of R1 and R2 represent a C1-6 alkyl group, R3 represents a C1-6 alkyl group which may contain one or more substituent groups selected from group A, or a C3-8 cycloalkyl group which may contain one or more substituent groups selected from group B.) which represents the compound, and salts thereof, solvates thereof, and medicinal compositions containing any of these.
摘要翻译：公开了含有血管紧张素II受体阻断和PPARγ活化作用的新型化合物和药物制剂，用作预防和/或治疗高血压，心脏病，心绞痛，脑血管障碍，脑循环障碍，缺血性外周循环损伤，肾脏疾病，动脉硬化，炎性疾病，2型糖尿病，糖尿病并发症，胰岛素抵抗综合征，X综合征，代谢综合征和高胰岛素血症。进一步公开的是通式I（其中R 1和R 2中的一个或两个表示C 1-6烷基，R 3表示可以含有一个或多个选自A组的取代基的C 1-6烷基或C 3-8 可以含有一个或多个选自B组的取代基的环烷基），其代表该化合物及其盐，其溶剂合物，以及含有这些中的任何一种的药物组合物。

3. 发明授权

US08273766B2 Tetrahydroisoquinoline compound 失效
标题翻译：四氢异喹啉化合物
公开(公告)号：US08273766B2
公开(公告)日：2012-09-25
申请号：US12531318
申请日：2008-04-03
申请人： Seiichi Sato , Junya Tagashira , Shunji Takemura , Yoshiharu Miyake , Tetsuya Ishikawa , Toshiharu Arai , Takahiro Ito , Takuya Hara
发明人： Seiichi Sato , Junya Tagashira , Shunji Takemura , Yoshiharu Miyake , Tetsuya Ishikawa , Toshiharu Arai , Takahiro Ito , Takuya Hara
IPC分类号： C07D217/18 , A61K31/47
CPC分类号： C07D217/04 , A61K31/472 , A61K31/4725 , C07D217/02 , C07D217/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12
摘要： The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.
摘要翻译：本发明涉及可用作3型趋化因子受体（CCR3）拮抗剂的特定四氢异喹啉化合物，以及包含其作为活性成分的药物组合物。本发明的四氢异喹啉化合物可用于治疗或预防CCR3参与的疾病。

4. 发明申请

US20120165353A1 NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME 有权
标题翻译：新颖的苯丙氨酸衍生物和药物包括它们
公开(公告)号：US20120165353A1
公开(公告)日：2012-06-28
申请号：US13394266
申请日：2010-09-29
申请人： Toru Miura , Seiichi Sato , Hajime Yamada , Junya Tagashira , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
发明人： Toru Miura , Seiichi Sato , Hajime Yamada , Junya Tagashira , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
IPC分类号： A61K31/506 , C07D413/14 , A61P9/00 , A61P13/12 , A61P3/10 , A61P9/10 , A61P9/12 , C07D401/14 , A61P3/00
CPC分类号： C07D401/14 , A61K31/422 , A61K31/4427 , C07D413/14
摘要： Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPARγ-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound. Specifically disclosed are: a compound represented by general formula (I) (wherein the ring A represents a pyridine ring; the ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents a C1-6 alkyl group; R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group; and R3, R4, R5 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo-C1-6 alkyl group, or a C1-6 alkoxy group which may have a substituent), a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition containing the compound, the salt or the solvate.
摘要翻译：公开了一种对血管紧张素II受体具有拮抗作用和PPARγ活化活性的新型化合物，因此可用作高血压，心脏病，动脉硬化，2型糖尿病，糖尿病并发症的预防和/或治疗剂，代谢综合征等; 和含有该化合物的药物组合物。具体公开的是：由通式（I）表示的化合物（其中环A表示吡啶环;环B表示四唑环或恶二唑-5（4H） - 酮环; X表示C-R5或氮原子; R1表示C1-6烷基; R2表示C1-6烷基或C3-8环烷基; R3，R4，R5分别表示氢原子，卤素原子，C1-6烷基，卤代C 1-6烷基或可具有取代基的C 1-6烷氧基），化合物的盐或化合物或其盐的溶剂合物; 和含有该化合物，该盐或溶剂化物的药物组合物。

5. 发明申请

US20120028983A1 NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME 失效
标题翻译：具有3-叔丁基嘧啶-4-（3H） - 酮结构的新型化合物和含有它们的药物制备
公开(公告)号：US20120028983A1
公开(公告)日：2012-02-02
申请号：US13263023
申请日：2010-04-16
申请人： Toru Miura , Kazuhiro Onogi , Seiichi Sato , Junya Tagashira , Gen Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
发明人： Toru Miura , Kazuhiro Onogi , Seiichi Sato , Junya Tagashira , Gen Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
IPC分类号： A61K31/53 , C07D403/14 , C07D413/14 , C07D417/14 , A61P13/12 , A61P3/00 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , C07D401/14 , A61K31/513
CPC分类号： C07D401/14 , C07D403/14 , C07D413/14 , C07D417/14
摘要： Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R1 and R2 independently represent a C1-6 alkyl group; and each of R3 to R5 is absent or represents H, a halogen atom, OH, NO2, a halo-C1-6 alkyl group, a (substituted) C1-6 alkoxy group, a (substituted) C3-6 cycloalkyloxy group, or a 5- to 10-membered heteroaryl group.]
摘要翻译：公开了具有血管紧张素-II受体拮抗作用和PPARγ活化活性的化合物，可用作高血压，心脏病，心绞痛，脑血管病，脑循环障碍，缺血性外周循环障碍的预防和/或治疗剂肾脏疾病，动脉硬化，炎性疾病，2型糖尿病，糖尿病并发症，胰岛素抵抗综合征，X综合征，代谢综合征和高胰岛素血症。 [式中，A表示5至10元杂芳基; R1和R2独立地表示C1-6烷基; 并且R 3至R 5不存在或表示H，卤素原子，OH，NO 2，卤代C 1-6烷基，（取代的）C 1-6烷氧基，（取代的）C 3-6环烷氧基或 5至10元杂芳基。]

6. 发明申请

US20100222347A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA, COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT 审中-公开
标题翻译：抗坏血酸和/或治疗药物，包括作为活性成分的四氢喹啉化合物
公开(公告)号：US20100222347A1
公开(公告)日：2010-09-02
申请号：US12680307
申请日：2008-09-29
申请人： Masanori Ashikawa , Junya Tagashira , Akiyasu Koketsu , Toshiharu Morimoto , Tatsuaki Nishiyama , Satoshi Goda , Masaki Yamabi , Takeshi Doi , Hiroyuki Ishiwata
发明人： Masanori Ashikawa , Junya Tagashira , Akiyasu Koketsu , Toshiharu Morimoto , Tatsuaki Nishiyama , Satoshi Goda , Masaki Yamabi , Takeshi Doi , Hiroyuki Ishiwata
IPC分类号： A61K31/5377 , C07D215/08 , A61K31/4706 , C07D413/12 , C07D215/233 , A61K31/47 , A61P7/00
CPC分类号： C07D215/48 , A61K31/47 , A61K31/4706 , A61K31/4709 , A61K31/496 , A61K31/5377 , C07D215/22 , C07D215/44 , C07D413/04 , C07D413/12
摘要： Disclosed is a low-molecular-weight compound having an EPO production-promoting activity and/or a hemoglobin expression-enhancing activity. Specifically disclosed is an EPO production promoter and/or a hemoglobin expression enhancer comprising a 1-acyl-4-(phenoxy, benzyloxy or phenylamino)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by the general formula (1); [wherein R1, R2, R2′, R3 and R3′ independently represent a hydrogen atom, a C1-6 alkyl group, or the like; R4, R5, R6, R7, R8, R9 and R10 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or the like; A represents N—R11 or an oxygen atom; R11 represents a hydrogen atom, a C1-6 alkyl group, or the like; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.
摘要翻译：公开了具有EPO生产促进活性和/或血红蛋白表达增强活性的低分子量化合物。具体公开的是EPO生产促进剂和/或血红蛋白表达增强剂，其包含1-酰基-4-（苯氧基，苄氧基或苯基氨基）-1,2,3,4-四氢喹啉衍生物，更具体地是由通式公式1）; [其中R1，R2，R2'，R3和R3'独立地表示氢原子，C1-6烷基等; R 4，R 5，R 6，R 7，R 8，R 9和R 10独立地表示氢原子，卤素原子，C 1-6烷基等; A表示N-R11或氧原子; R 11表示氢原子，C 1-6烷基等; n表示0或1的整数]，四氢喹啉化合物的盐或四氢喹啉化合物或其盐的溶剂合物。

7. 发明申请

US20100120844A1 TETRAHYDROISOQUINOLINE COMPOUND 失效
标题翻译：四氢喹啉化合物
公开(公告)号：US20100120844A1
公开(公告)日：2010-05-13
申请号：US12531318
申请日：2008-04-03
申请人： Seiichi Sato , Junya Tagashira , Shunji Takemura , Yoshiharu Miyake , Tetsuya Ishikawa , Toshiharu Arai , Takahiro Ito , Takuya Hara
发明人： Seiichi Sato , Junya Tagashira , Shunji Takemura , Yoshiharu Miyake , Tetsuya Ishikawa , Toshiharu Arai , Takahiro Ito , Takuya Hara
IPC分类号： A61K31/4709 , C07D401/02 , C07D217/18 , A61K31/47 , A61P11/06 , A61P31/18 , A61P37/06 , A61P1/00
CPC分类号： C07D217/04 , A61K31/472 , A61K31/4725 , C07D217/02 , C07D217/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12
摘要： The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.
摘要翻译：本发明涉及可用作3型趋化因子受体（CCR3）拮抗剂的特定四氢异喹啉化合物，以及包含其作为活性成分的药物组合物。本发明的四氢异喹啉化合物可用于治疗或预防CCR3参与的疾病。

8. 发明授权

US08791090B2 Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient 有权
标题翻译：含有四氢喹啉化合物作为活性成分的贫血的预防和/或治疗剂
公开(公告)号：US08791090B2
公开(公告)日：2014-07-29
申请号：US13256549
申请日：2010-03-31
申请人： Masanori Ashikawa , Junya Tagashira , Akiyasu Koketsu , Toshiharu Morimoto , Takahiro Kitamura , Syunji Takemura , Gen Watanabe , Tatsuaki Nishiyama , Satoshi Goda , Masaki Yamabi , Takeshi Doi , Hiroyuki Ishiwata
发明人： Masanori Ashikawa , Junya Tagashira , Akiyasu Koketsu , Toshiharu Morimoto , Takahiro Kitamura , Syunji Takemura , Gen Watanabe , Tatsuaki Nishiyama , Satoshi Goda , Masaki Yamabi , Takeshi Doi , Hiroyuki Ishiwata
IPC分类号： A01N57/00 , A61K31/385
CPC分类号： C07D215/42 , A61K31/47 , A61K31/4706 , A61K31/4709 , A61K31/496 , A61K31/5377 , A61K31/69 , C07D215/233 , C07D215/44 , C07D215/46 , C07D215/48 , C07D401/04 , C07D401/12 , C07D405/12 , C07D413/04 , C07D413/12 , C07D417/12
摘要： Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R1, R2, R2′, R3 and R3′ independently represent a hydrogen atom, a C1-6 alkyl group, or the like; R4, R5, R6, R7, R8, R9 and R10 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or the like; A represents N—R11, a sulfur atom, or an oxygen atom; R11 represents a hydrogen atom, a C1-6 alkyl group, or the like; B represents a C6-14 aryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.
摘要翻译：公开了具有低分子量且具有增强EPO产生活性和/或提高血红蛋白生成活性的化合物。具体公开的是EPO生产增强剂和/或包含1-酰基-4-（取代的氧基，取代的氨基或取代的硫代）-1,2,3,4-四氢喹啉衍生物，更具体地是四氢喹啉化合物的血红蛋白生成增强剂由通式（1）表示[其中R1，R2，R2'，R3和R3'独立地表示氢原子，C1-6烷基等; R 4，R 5，R 6，R 7，R 8，R 9和R 10独立地表示氢原子，卤素原子，C 1-6烷基等; A表示N-R11，硫原子或氧原子; R 11表示氢原子，C 1-6烷基等; B表示C 6-14芳基或5至10元杂环基; n表示0或1的整数]，四氢喹啉化合物的盐或四氢喹啉化合物或其盐的溶剂合物。

9. 发明授权

US08778954B2 Phenylpyridine derivative and medicinal agent comprising same 有权
标题翻译：苯基吡啶衍生物和含有它们的药剂
公开(公告)号：US08778954B2
公开(公告)日：2014-07-15
申请号：US13394266
申请日：2010-09-29
申请人： Toru Miura , Seiichi Sato , Hajime Yamada , Junya Tagashira , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
发明人： Toru Miura , Seiichi Sato , Hajime Yamada , Junya Tagashira , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
IPC分类号： C07D401/14 , A61K31/422 , A61K31/4427
CPC分类号： C07D401/14 , A61K31/422 , A61K31/4427 , C07D413/14
摘要： Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPARγ-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound. Specifically disclosed are: a compound represented by general formula (I) (wherein the ring A represents a pyridine ring; the ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents a C1-6 alkyl group; R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group; and R3, R4, R5 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo-C1-6 alkyl group, or a C1-6 alkoxy group which may have a substituent), a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition containing the compound, the salt or the solvate.
摘要翻译：公开了一种对血管紧张素II受体具有拮抗作用和PPARγ活化活性的新型化合物，因此可用作高血压，心脏病，动脉硬化，2型糖尿病，糖尿病并发症的预防和/或治疗剂，代谢综合征等; 和含有该化合物的药物组合物。具体公开的是：由通式（I）表示的化合物（其中环A表示吡啶环;环B表示四唑环或恶二唑-5（4H） - 酮环; X表示C-R5或氮原子; R1表示C1-6烷基; R2表示C1-6烷基或C3-8环烷基; R3，R4，R5分别表示氢原子，卤素原子，C1-6烷基，卤代C 1-6烷基或可具有取代基的C 1-6烷氧基），化合物的盐或化合物或其盐的溶剂合物; 和含有该化合物，该盐或溶剂化物的药物组合物。

10. 发明授权

US08664226B2 Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same 失效
标题翻译：具有3-杂芳基嘧啶-4-（3H） - 酮结构的化合物和含有它们的药物制剂
公开(公告)号：US08664226B2
公开(公告)日：2014-03-04
申请号：US13263023
申请日：2010-04-16
申请人： Toru Miura , Kazuhiro Onogi , Seiichi Sato , Junya Tagashira , Gen Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
发明人： Toru Miura , Kazuhiro Onogi , Seiichi Sato , Junya Tagashira , Gen Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
IPC分类号： C07D401/14 , A61K31/506
CPC分类号： C07D401/14 , C07D403/14 , C07D413/14 , C07D417/14
摘要： Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R1 and R2 independently represent a C1-6 alkyl group; and each of R3 to R5 is absent or represents H, a halogen atom, OH, NO2, a halo-C1-6 alkyl group, a (substituted) C1-6 alkoxy group, a (substituted) C3-6 cycloalkyloxy group, or a 5- to 10-membered heteroaryl group.]
摘要翻译：公开了具有血管紧张素-II受体拮抗作用和PPARγ活化活性的化合物，可用作高血压，心脏病，心绞痛，脑血管障碍，脑循环障碍，缺血性外周循环障碍的预防和/或治疗剂肾脏疾病，动脉硬化，炎性疾病，2型糖尿病，糖尿病并发症，胰岛素抵抗综合征，X综合征，代谢综合征和高胰岛素血症。 [式中，A表示5至10元杂芳基; R1和R2独立地表示C1-6烷基; 并且R 3至R 5不存在或表示H，卤素原子，OH，NO 2，卤代C 1-6烷基，（取代的）C 1-6烷氧基，（取代的）C 3-6环烷氧基或 5至10元杂芳基。]

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式